Last updated: February 14, 2026
Overview
NDC 00310-6270 refers to Sotorasib (Lyo & Sol), marketed as Lumakras by Amgen. It is the first FDA-approved KRAS G12C inhibitor for non-small cell lung cancer (NSCLC). The drug was approved in May 2021 and targets a common mutation present in approximately 13% of NSCLC cases.
Market Size and Demand Drivers
- Target Population: Approximately 200,000 new NSCLC cases annually in the U.S. (2022 data), with about 13% harboring the G12C mutation.
- Prevalence Estimate: Estimated 26,000 eligible patients annually for treatment in the U.S.
- Competitive Landscape: Limited direct competition; other KRAS inhibitors are in development but none approved. Key competitors include experimental agents like Amgen’s own experimental compounds and potential pipeline entrants.
Market Penetration Factors
- Reimbursement and Approvals: Positive reimbursement outlook, given FDA approval and inclusion in NCCN guidelines.
- Physician Adoption: High adoption rate expected, given targeted therapy’s precision and initial data demonstrating efficacy.
- Pricing Strategy: Priced at a premium, reflecting rarity and targeting a serious unmet need.
Pricing Trends and Projections
- Initial Pricing: The wholesale acquisition cost (WAC) is approximately $17,900 per 28-day supply (as of 2022).
- Cost-Effectiveness: High cost justified by efficacy; cost per quality-adjusted life year (QALY) exceeds traditional thresholds, but accepted within oncology for targeted therapies.
- Market Penetration Projections (2023–2027):
| Year |
Estimated Patients Treated |
Total Revenue (USD millions) |
Assumptions |
| 2023 |
8,000 |
1,938 |
31% market penetration; drug used in first-line settings |
| 2024 |
12,000 |
2,908 |
Increased adoption, expanded indications |
| 2025 |
15,000 |
3,643 |
Broader recognition, higher brand awareness |
| 2026 |
18,000 |
4,370 |
Saturation of eligible patient population |
| 2027 |
20,000 |
4,850 |
Peak market, slight increase due to broader use |
Note: These projections are conservative, assuming steady growth and no significant competition or pipeline breakthroughs.
Currency and Pricing Factors
- Pricing Adjustments: Possible discounts (~10-20%) for volume or insurance negotiations.
- International Pricing: Typically lower than U.S., around 50-70% of U.S. prices depending on country.
Regulatory and Policy Considerations
- Reimbursement: CMS and private payers indicate coverage for targeted treatments; access influence remains.
- Pricing Regulation: Growing debate on drug pricing strategies and potential regulation, particularly for oncology therapies, could influence future price patterns.
Key Market Risks
- Emerging Competition: New KRAS inhibitors or combination therapies could impact market share.
- Pricing Pressure: Payer push for price reductions or value-based agreements.
- Treatment Guidelines: Shifts towards combination therapies or alternative targeted agents may reshape demand.
Summary
NDC 00310-6270 (Lumakras) is positioned as a first-in-class KRAS G12C inhibitor with strong initial uptake driven by its targeted mechanism and regulatory approvals. Its premium pricing, combined with limited competition, indicates robust revenue potential, with revenues projected to grow steadily over the next five years as adoption deepens.
Key Takeaways
- Lumakras’s market entry has established a significant niche in NSCLC treatment.
- Pricing remains high, reflecting the drug's targeted, rarity-status indication.
- Market growth depends on expansion beyond monotherapy to combination regimens and broader indications.
- Competition from pipeline drugs may influence future market share and pricing.
- Ongoing regulatory and reimbursement policies will play critical roles in market penetration.
FAQs
-
What factors influence Lumakras’s pricing strategy?
The drug’s high cost reflects its targeted mechanism, rarity of the mutation, and lack of direct competition. Pricing considers reimbursement negotiations, value demonstrated in clinical trials, and the cost of development.
-
How might emerging competitors impact Lumakras’s market?
New KRAS inhibitors in late-stage development could erode market share, especially if they demonstrate superior efficacy, safety, or cost-effectiveness.
-
What is the typical patient population for Lumakras?
Patients with metastatic NSCLC harboring the KRAS G12C mutation, approximately 13% of NSCLC cases, estimated at around 26,000 annually in the U.S.
-
Is Lumakras approved for other indications?
Currently approved for KRAS G12C-mutated NSCLC; clinical trials are exploring use in other cancers such as colorectal and pancreatic cancers.
-
What policy factors could influence Lumakras’s future prices?
Policy debates on drug pricing, value-based arrangements, and reimbursement reforms could lead to price adjustments or usage restrictions in certain markets.
Sources
[1] FDA Approval Announcement, Amgen.
[2] MarketData, IQVIA, 2022.
[3] NCCN Guidelines, 2022.
[4] Clinical Trial Data, ClinicalTrials.gov.
[5] Pricing Benchmarks, Wholesale Acquisition Cost Reports, 2022.
